An analysis of PD-L1 expression levels in 871 Chinese NSCLC samples showed that patients with EGFR mutations had slightly lower PD-L1 positivity (43.8% and 49.8%, respectively), while higher PD-L1 expression (TPS ≥ 50%) was significantly lower (14.3% and 27.4%, respectively) compared with EGFR wild-type patients 18. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.